Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design
Diabetic Medicine · 2026-07 · 43 (7)
DOI: 10.1111/dme.70328 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetic Medicine, online erschienen am 15.04.2026. Verfasst von Caren Sourij und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Caloric Restriction, Diabetes Mellitus, Type 2, Exercise Therapy, Intermittent Fasting. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Lifestyle modification, including caloric restriction and exercise, is fundamental in the treatment of people living with overweight and type 2 diabetes mellitus (T2D). The overall aim of lifestyle intervention schemes is to reduce body weight and improve glycaemic control to reduce the future risk of diabetes‐associated complications. The aim of this study is to determine whether intermittent energy restriction, exercise or their combination is best suited for reaching these targets in individuals with T2D not treated with insulin.
Methods
This randomized, controlled, monocentric parallel‐group trial is designed to investigate participants living with T2D, body mass index >27 kg/m 2 , HbA1c ≥53 mmol/mol (≥7.0%) and ≤86 mmol/mol (≤10.0%) and without insulin therapy. Participants are equally and randomly allocated to one of four study groups: (1) intermittent energy restriction group, (2) exercise group, (3) combined intermittent energy restriction and exercise group and (4) control group. The intervention phase lasts 12 weeks, followed by a two‐year follow‐up phase. In addition to assessing body weight and glycaemic parameters, resting energy expenditure (REE) and body composition are measured. An oral glucose tolerance test is carried out at baseline and at the end of the intervention. Additionally, stool samples for microbiome analyses and individual‐related outcomes are collected, and all participants are equipped with continuous glucose monitoring (CGM). The primary outcome measure is the change in bodyweight from baseline to day 84. Trial Registration The study was registered at DRKS (Deutsches Register Klinischer Studien—German Clinical Trial Register DRKS‐ID: DRKS00032036)—Date of registration: 11.10.2023.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Medical University of Graz, Graz, Austria.
- Cardiometabolic Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
- Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
- Department for Medical Psychology, Psychosomatic and Psychotherapy, Medical University of Graz, Graz, Austria.
ORCID-Profile: Norbert J Tripolt
Förderung
- Austrian Science Fund
Zitieren
APA
Sourij, C., Müller, A., Al-Baghdadi, A., Aziz, F., Tripolt, N. J., Pferschy, P. N., Andritz, E., Kojzar, H., Stadlbauer, V., Garcia, S. L., & Sourij, H. (2026). Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design. Diabetic Medicine, 43(7). https://doi.org/10.1111/dme.70328
Vancouver
Sourij C, Müller A, Al-Baghdadi A, Aziz F, Tripolt NJ, Pferschy PN, et al. Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design. Diabetic Medicine. 2026;43(7). doi:10.1111/dme.70328
BibTeX
@article{Sourij2026,
author = {Sourij, Caren and Müller, Alexander and Al-Baghdadi, Abdullah and Aziz, Faisal and Tripolt, Norbert J and Pferschy, Peter N and Andritz, Eva and Kojzar, Harald and Stadlbauer, Vanessa and Garcia, Sabrina Leal and Sourij, Harald},
title = {Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design},
journal = {Diabetic Medicine},
year = {2026},
volume = {43},
number = {7},
doi = {10.1111/dme.70328}
}
EUVIMED